Risk factors for lung function decline in a large cohort of young cystic fibrosis patients

Pediatric Pulmonology

Volumn 50, Issue 8, 2015, Pages 763-770

  Cogen, Jonathan ^a   Emerson, Julia ^a   Sanders, Don B ^b   Ren, Clement ^c   Schechter, Michael S ^d   Gibson, Ronald L ^a   Morgan, Wayne ^e   Rosenfeld, Margaret ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UW American Family Children's Hospital   (United States)

^c UNIVERSITY OF ROCHESTER   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^e UNIVERSITY OF ARIZONA   (United States)

Author keywords

cystic fibrosis; decline; EPIC Observational Study; lung function; pediatric; Pseudomonas aeruginosa

Indexed keywords

PANCREAS ENZYME; PHENYLALANINE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR;

ARTICLE; BODY MASS; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; COUGHING; CYSTIC FIBROSIS; DEMOGRAPHY; DISEASE EXACERBATION; ENVIRONMENTAL FACTOR; FEMALE; FORCED EXPIRATORY VOLUME; GENDER; GENE DELETION; HIGH RISK PATIENT; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; STENOTROPHOMONAS MALTOPHILIA; UNITED STATES; ADOLESCENT; CLINICAL TRIAL; DISEASE COURSE; FOLLOW UP; GENETICS; GENOTYPE; HETEROZYGOTE; MICROBIOLOGY; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; SEX DIFFERENCE; STAPHYLOCOCCUS AUREUS;

ADOLESCENT; CHILD; COUGH; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA; UNITED STATES;

EID: 84937023882     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.23217     Document Type: Article

References (31)

1. Corey M, Edwards L, Levison H, Knowles M,. Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis. J Pediatr 1997; 131: 809-814.
2. Schluchter MD, Konstan MW, Davis PB,. Jointly modelling the relationship between survival and pulmonary function in cystic fibrosis patients. Stat Med 2002; 21: 1271-1287.
3. Konstan MW, Byard PJ, Hoppel CL, Davis PB,. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995; 332: 848-854.
4. Ren CL, Pasta DJ, Rasouliyan L, Wagener JS, Konstan MW, Morgan WJ, Scientific Advisory G, the Investigators, Coordinators of the Epidemiologic Study of Cystic F. Relationship between inhaled corticosteroid therapy and rate of lung function decline in children with cystic fibrosis. J Pediatr 2008; 153: 746-751.
5. Konstan MW, Wagener JS, Pasta DJ, Millar SJ, Jacobs JR, Yegin A, Morgan WJ, Scientific Advisory G, Investigators, Coordinators of Epidemiologic Study of Cystic F. Clinical use of dornase alpha is associated with a slower rate of FEV1 decline in cystic fibrosis. Pediatr Pulmonol 2011; 46: 545-553.
6. McPhail GL, Acton JD, Fenchel MC, Amin RS, Seid M,. Improvements in lung function outcomes in children with cystic fibrosis are associated with better nutrition, fewer chronic Pseudomonas aeruginosa infections, and dornase alfa use. J Pediatr 2008; 153: 752-757.
7. Schaedel C, de Monestrol I, Hjelte L, Johannesson M, Kornfalt R, Lindblad A, Strandvik B, Wahlgren L, Holmberg L,. Predictors of deterioration of lung function in cystic fibrosis. Pediatr Pulmonol 2002; 33: 483-491.
8. Konstan MW, Morgan WJ, Butler SM, Pasta DJ, Craib ML, Silva SJ, Stokes DC, Wohl ME, Wagener JS, Regelmann WE, Johnson CA,. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr 2007; 151: 134-139, 139 e131.
9. Sanders DB, Li Z, Laxova A, Rock MJ, Levy H, Collins J, Ferec C, Farrell PM,. Risk factors for the progression of cystic fibrosis lung disease throughout childhood. Ann Am Thorac Soc 2014; 11: 63-72.
10. Welsh L, Robertson CF, Ranganathan SC,. Increased rate of lung function decline in Australian adolescents with cystic fibrosis. Pediatr Pulmonol 2014; 49: 873-877.
11. Waters V, Stanojevic S, Atenafu EG, Lu A, Yau Y, Tullis E, Ratjen F,. Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis. Eur Respir J 2012; 40: 61-66.
12. Vandenbranden SL, McMullen A, Schechter MS, Pasta DJ, Michaelis RL, Konstan MW, Wagener JS, Morgan WJ, McColley SA, Investigators, Coordinators of the Epidemiologic Study of Cystic F. Lung function decline from adolescence to young adulthood in cystic fibrosis. Pediatr Pulmonol 2012; 47: 135-143.
13. Treggiari MM, Rosenfeld M, Mayer-Hamblett N, Retsch-Bogart G, Gibson RL, Williams J, Emerson J, Kronmal RA, Ramsey BW,. Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemp Clin Trials 2009; 30: 256-268.
14. Rosenfeld M, Emerson J, McNamara S, Joubran K, Retsch-Bogart G, Graff GR, Gutierrez HH, Kanga JF, Lahiri T, Noyes B, Ramsey B, Ren CL, Schechter M, Morgan W, Gibson RL,. Baseline characteristics and factors associated with nutritional and pulmonary status at enrollment in the cystic fibrosis EPIC observational cohort. Pediatr Pulmonol 2010; 45: 934-944.
15. Farrell PM, Rosenstein BJ, White TB, Accurso FJ, Castellani C, Cutting GR, Durie PR, Legrys VA, Massie J, Parad RB, Rock MJ, Campbell PW,. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr 2008; 153: S4-S14.
16. Wang X, Dockery DW, Wypij D, Gold DR, Speizer FE, Ware JH, Ferris BG, Jr., Pulmonary function growth velocity in children 6 to 18 years of age. Am Rev Respir Dis 1993; 148: 1502-1508.
17. Hankinson JL, Odencrantz JR, Fedan KB,. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999; 159: 179-187.
18. Tam A, Morrish D, Wadsworth S, Dorscheid D, Man SF, Sin DD,. The role of female hormones on lung function in chronic lung diseases. BMC Womens Health 2011; 11: 24.
19. Zeitlin PL,. Cystic fibrosis and estrogens: a perfect storm. J Clin Invest 2008; 118: 3841-3844.
20. Li Z, Kosorok MR, Farrell PM, Laxova A, West SE, Green CG, Collins J, Rock MJ, Splaingard ML,. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 2005; 293: 581-588.
21. Dasenbrook EC, Merlo CA, Diener-West M, Lechtzin N, Boyle MP,. Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. Am J Respir Crit Care Med 2008; 178: 814-821.
22. Pillarisetti N, Williamson E, Linnane B, Skoric B, Robertson CF, Robinson P, Massie J, Hall GL, Sly P, Stick S, Ranganathan S,. Infection, inflammation, and lung function decline in infants with cystic fibrosis. Am J Respir Crit Care Med 2011; 184: 75-81.
23. Weaver LT, Green MR, Nicholson K, Mills J, Heeley ME, Kuzemko JA, Austin S, Gregory GA, Dux AE, Davis JA,. Prognosis in cystic fibrosis treated with continuous flucloxacillin from the neonatal period. Arch Dis Child 1994; 70: 84-89.
24. Stutman HR, Lieberman JM, Nussbaum E, Marks MI,. Antibiotic prophylaxis in infants and young children with cystic fibrosis: a randomized controlled trial. J Pediatr 2002; 140: 299-305.
25. Stanojevic S, Ratjen F, Stephens D, Lu A, Yau Y, Tullis E, Waters V,. Factors influencing the acquisition of Stenotrophomonas maltophilia infection in cystic fibrosis patients. J Cyst Fibros 2013; 12: 575-583.
26. Morgan WJ, Wagener JS, Yegin A, Pasta DJ, Millar SJ, Konstan MW, Scientific Advisory Group i, coordinators of the Epidemiologic Study of Cystic F. Probability of treatment following acute decline in lung function in children with cystic fibrosis is related to baseline pulmonary function. J Pediatr 2013; 163: 1152-1157, e1152.
27. Yen EH, Quinton H, Borowitz D,. Better nutritional status in early childhood is associated with improved clinical outcomes and survival in patients with cystic fibrosis. J Pediatr 2013; 162: 530-535, e531.
28. Ortiz JR, Neuzil KM, Victor JC, Wald A, Aitken ML, Goss CH,. Influenza-associated cystic fibrosis pulmonary exacerbations. Chest 2010; 137: 852-860.
29. Schechter MS, Shelton BJ, Margolis PA, Fitzsimmons SC,. The association of socioeconomic status with outcomes in cystic fibrosis patients in the United States. Am J Respir Crit Care Med 2001; 163: 1331-1337.
30. Taylor-Robinson DC, Thielen K, Pressler T, Olesen HV, Diderichsen F, Diggle PJ, Smyth R, Whitehead M,. Low socioeconomic status is associated with worse lung function in the Danish cystic fibrosis population. Eur Respir J 2014; 44: 1363-1366.
31. Rosenfeld M, Emerson J, Accurso F, Armstrong D, Castile R, Grimwood K, Hiatt P, McCoy K, McNamara S, Ramsey B, Wagener J,. Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. Pediatr Pulmonol 1999; 28: 321-328.